Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Maarten R Seefat

6PUBLICATIONS

13CO-AUTHORS

Predictive and prognostic markersPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Dec 10, 2025

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Kazimierz Groen, Febe Smits, Kazem Nasserinejad

|Nov 03, 2025

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.

M R Seefat, D G J Cucchi, L van Boven

|Aug 22, 2025

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Febe Smits, Kaz Groen, Mark-David Levin

|Nov 22, 2024

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.

Febe Smits, Kaz Groen, Mark-David Levin

|Oct 11, 2023

Treatment sequences and drug costs from diagnosis to death in multiple myeloma.

M R Seefat, D G J Cucchi, K Groen

|Nov 27, 2021

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma.

Maarten R Seefat, David G J Cucchi, Stijn Dirven

Pageof 1

Frequent Collaborators

3 joint publications

Sonja Zweegman

2 joint publications

David G J Cucchi

2 joint publications

Niels W C J van de Donk

2 joint publications

Hedwig M Blommestein

2 joint publications

Mark-David Levin

2 joint publications

Yorick Sandberg

2 joint publications

Alain Kentos

2 joint publications

Nicole C H P de Graauw

1 joint publications

C L B M Korst

1 joint publications

R Mathot

Frequent Collaborators

3 joint publications

Sonja Zweegman

2 joint publications

David G J Cucchi

2 joint publications

Niels W C J van de Donk

2 joint publications

Hedwig M Blommestein

Top Related Videos

Interphase Fluorescence <em>in situ</em> Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence <em>in situ</em> Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on : Apr 15, 2022

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on : May 15, 2019

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on : Jul 24, 2013

See more related videos

Top Related Videos

Interphase Fluorescence <em>in situ</em> Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence <em>in situ</em> Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on : Apr 15, 2022

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on : May 15, 2019

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on : Jul 24, 2013

See more related videos